• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

July 2, 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Author(s):

Alexandra Gerlach, Associate Editor

Fact checked by:

Alana Hippensteele, Lead Editor

Key Takeaways

  • Estrogen plus progestin therapy is linked to a modestly increased risk of young-onset breast cancer, especially with prolonged use and in women with intact uteri and ovaries.
  • Estrogen-only therapy is associated with a reduced risk of young-onset breast cancer, suggesting differential impacts of hormone therapy formulations.
  • The study underscores the importance of personalized medical advice, weighing symptom relief benefits against potential breast cancer risks in hormone therapy decisions.
  • Subtype-specific analysis indicates stronger associations of EP-HRT with estrogen receptor–negative and triple-negative breast cancer, suggesting biological differences in hormone sensitivity.
SHOW MORE

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

Study findings suggest a positive association between estrogen plus progestin hormone replacement therapy (EP-HRT) and increased risk of breast cancer in young adult women. The data, published in Lancet Oncology, may provide deeper insight into the potential risks of specific HRT types in pre- and postmenopausal women to better guide clinical decision-making.1

HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com

HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com

“Hormone therapy can greatly improve the quality of life for women experiencing severe menopausal symptoms or those who have had surgeries that affect their hormone levels,” Katie O’Brien, PhD, lead author of National Institutes of Health (NIH)’s National Institute of Environmental Health Sciences (NIEHS), said in an official NIH release. “Our study provides greater understanding of the risks associated with different types of hormone therapy, which we hope will help patients and their doctors develop more informed treatment plans.”2

Hormone replacement therapy (HRT) is often used to ease the symptoms of menopause, such as hot flashes, vaginal dryness, and mood swings, that arise as estrogen levels naturally decline with age. It may also be recommended for individuals who have undergone a hysterectomy or oophorectomy. There are 2 main types of HRT: estrogen-only therapy (E-HRT), typically reserved for those who no longer have a uterus, and combined estrogen-progestin therapy (EP-HRT), which is used when the uterus is intact to help reduce the risk of endometrial cancer.2,3

Studies confirm that estrogen plus progestin is a risk factor for breast cancer in postmenopausal women, but there are little data on the impact of these therapies in young women who may need HRT following gynecological surgery or for perimenopausal symptom relief. In a pooled cohort analysis, an international team of researchers at the NIH investigated the relationship between exogenous hormone therapy and the risk of young-onset breast cancer, drawing on data from 10 to 13 prospective cohort studies conducted across North America, Europe, Asia, and Australia. This large-scale analysis followed women up to age 55, focusing on the impact of hormone therapy (HT; used interchangeably with HRT) on breast cancer incidence in younger populations—a group for whom data has historically been limited.1,2

A total of 459,476 women between the ages of 16 and 54 years (mean age 42.0 years) were included in the study. Over a median follow-up of 7.8 years, 2% of participants (n = 8455) were diagnosed with breast cancer before age 55. HT use was reported by 15% of participants, with the most common regimens being estrogen plus progestin therapy (6%) and unopposed estrogen (5%).1

The researchers found no overall association between HT of any type and young-onset breast cancer (HR 0.96; 95% CI, 0.88–1.04). However, use of estrogen-only therapy was associated with a significantly lower risk (HR 0.86; 95% CI, 0.75–0.98), corresponding to a 0.5% absolute risk reduction by age 55.1

In contrast, combined estrogen plus progestin therapy was associated with a modestly elevated risk of young-onset breast cancer (HR 1.10; 95% CI, 0.98–1.24), particularly with longer duration of use (>2 years; HR 1.18; 95% CI, 1.01–1.38). The association was strongest among women with intact uteri and ovaries (HR 1.15; 95% CI, 1.02–1.31).1

The team also reported results from a subtype-specific analysis, which revealed that estrogen plus progestin therapy was more strongly associated with estrogen receptor–negative (HR 1.44; 95% CI, 1.11–1.88) and triple-negative breast cancer (HR 1.50; 95% CI, 1.02–2.20), suggesting potential biological differences in hormone sensitivity.1

These findings offer new insight into the differential impact of hormone therapy formulations on breast cancer risk in younger women. The results align with existing data on hormone therapy and later-onset breast cancer while highlighting the importance of individualized risk assessment when considering hormone use before age 55.

“These findings underscore the need for personalized medical advice when considering hormone therapy,” said Dale Sandler, PhD, NIEHS scientist and senior author, in an official NIH release. “Women and their health care providers should weigh the benefits of symptom relief against the potential risks associated with hormone therapy, especially EP-HT. For women with an intact uterus and ovaries, the increased risk of breast cancer with EP-HT should prompt careful deliberation.”2

REFERENCES
1. O’Brien K, House M, Goldberg M, et al. Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group. The Lancet Oncol. June 30, 2025. Doi: 10.1016/S1470-2045(25)00211-6
2. Breast cancer risk in younger women may be influenced by hormone therapy. NIH. June 30, 2025. Accessed July 2, 2025. http://nih.gov/news-events/news-releases/breast-cancer-risk-younger-women-may-be-influenced-hormone-therapy
3. Hormone therapy for menopause. American College of Obstetricians and Gynecologists. February 2024. Accessed July 2, 2025. https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com
Related Content
Advertisement
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
3d illustration of the heart and lung
July 2nd 2025

Lung Transplant Recipients at High Risk of Secondary Lung Infections Post-Infection With SARS-CoV-2 Omicron Variant

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
Clean eating, vegan healthy salad bowl closeup , woman holding salad bowl, plant based healthy diet with greens, chickpeas and vegetables - Image credit: marrakeshh | stock.adobe.com
July 1st 2025

Study Evaluates Impact of Dietary Acid Load on Weight Loss in Vegan and Mediterranean Diets

Kennedy Ferruggia, Assistant Editor
Related Content
Advertisement
pores on the skin of the face. Cleansing the face skin - Image credit: Angelina | stock.adobe.com
July 2nd 2025

Study Examines How Vitamin C Shapes Skin Health Through TET-Mediated Demethylation

Kennedy Ferruggia, Assistant Editor
Pharmacy Times, Pharmacy Focus Oncology Edition
June 27th 2025

Allen's Story: The Promising Potential of Intratumoral Immunotherapy

Alexandra Gerlach, Associate Editor
3d illustration of the heart and lung
July 2nd 2025

Lung Transplant Recipients at High Risk of Secondary Lung Infections Post-Infection With SARS-CoV-2 Omicron Variant

Luke Halpern, Assistant Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Sepsis - Image credit: Zerbor | stock.adobe.com
July 2nd 2025

FDA Approves Vancomycin Injection For Ready-to-Infuse Sepsis Therapy

Kennedy Ferruggia, Assistant Editor
Clean eating, vegan healthy salad bowl closeup , woman holding salad bowl, plant based healthy diet with greens, chickpeas and vegetables - Image credit: marrakeshh | stock.adobe.com
July 1st 2025

Study Evaluates Impact of Dietary Acid Load on Weight Loss in Vegan and Mediterranean Diets

Kennedy Ferruggia, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.